Alzheimer’s R&D In Brief: Roche’s Crenezumab Misses Endpoints, Novartis Plans Large New Genetic Study

21 Jul 2014

• By Emily Hayes

In data presented at the Alzheimer's Association International Conference in Copenhagen, held July 12-17, Roche’s anti-amyloid beta antibody misses endpoints in two Phase II studies, but there were some promising signs of efficacy.

Roche’s anti-amyloid beta monoclonal antibody crenezumab missed endpoints related to cognitive improvement in two Phase II Alzheimer’s disease trials with over 522 patients combined, but there were some positive data points. [Editor’s note: This story originally stated both trials had cognitive improvement as the primary endpoint; it was a secondary endpoint in the BLAZE trial.]

Roche has been developing the candidate with AC Immune SA.